

NEWSLETTER n°2



Pulmonary Embolism International Thrombolysis trial

A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism

EudraCT No.: 2018-000816-96; ClinicalTrials.gov Identifier: NCT04430569

Dear Investigators and study teams,

We are extremely happy to inform you that **13 patients** have already been included in PEITHO-3!

The **first patient** was enrolled on **4th August 2021** at site **n°001 Paris-APHP – HEGP (PI: Prof. Benjamin PLANQUETTE)**.

A special thank you to our **French and German sites** for your commitment and hard work to have the first patients included!



Alteplase 0.6 mg/kg
(not exceeding 50 mg)
intravenously over 15
minutes (along with
standard-of-care
heparin anticoagulation)



14 Countries

- Austria
- Belgium
- Canada
- France
- Germany
- Italy
- Netherlands
- Poland
- Portugal
- Romania
- Serbia
- Slovenia
- Spain
- Switzerland



83 Sites



650 Patients



Study Objective

To assess the efficacy of reduced dose thrombolytic therapy in patients with intermediate high-risk acute pulmonary embolism

What's happening in the PEITHO-3 study?

Site initiation

Up to now, **4 sites** out of 22 have been initiated in **France** and **4 sites** out of 20 in **Germany**.

We would like to thank all **Austrian, French and German sites** for your commitment, and are continuing our efforts to have all sites in all countries opened as fast as possible!

Regulatory submissions

Aixial and APHP are currently preparing the **regulatory submissions dossier for all other countries** to have them ready to start in the coming weeks.

Thank you again for your **contribution and patience** during this phase to set up the PEITHO-3 study in your country!

Steering Committee

Thank you for your participation at the first meeting of the steering committee that took place on 27th May 2021.

We are pleased to inform you that the **study design paper** that we discussed at this first steering committee meeting has meanwhile been published as an "open access" article in *Thrombosis and Haemostasis* (DOI: [10.1055/a-1653-4699](https://doi.org/10.1055/a-1653-4699))

Please do not hesitate to contact us if you need any further information and help.

Thank you again for your participation!

With our very best regards,

Prof. Olivier SANCHEZ and Prof. Stavros KONSTANTINIDES

The AP-HP and Aixial teams

| MAIN CONTACTS | |
|---|---|
| International Coordinators | Prof. Olivier SANCHEZ olivier.sanchez@aphp.fr Prof. Stavros KONSTANTINIDES stavros.konstantinides@unimedizin_mainz.de |
| APHP Clinical Project Manager | Yvann FRIGOUT yvann.frigout@aphp.fr Aurélie GUIMFACK aurelie.guimfack@aphp.fr |
| AIXIAL Global Clinical Operation Project Manager | Kelly LUTCHIA kelly.lutchia@aixial.com |